BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 22951648)

  • 1. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].
    Aktaş G; Bozdoğan B; Derbentli S
    Mikrobiyol Bul; 2012 Jul; 46(3):359-65. PubMed ID: 22951648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains].
    Efe S; Sinirtaş M; Ozakin C
    Mikrobiyol Bul; 2009 Oct; 43(4):639-43. PubMed ID: 20084917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Linezolid-resistant Enterococcus faecium: the first G2576T mutation in Turkey].
    Afşar I; Barış I; Sener AG; Köksal V; Demirci M
    Mikrobiyol Bul; 2012 Jul; 46(3):516-8. PubMed ID: 22951666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of linezolid combined with minocycline against vancomycin-resistant Enterococci.
    Wu J; Jiang TT; Su JR; Li L
    Chin Med J (Engl); 2013 Jul; 126(14):2670-5. PubMed ID: 23876894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro activity of daptomycin against VRE and MRSA strains].
    Aktaş G; Derbentli S
    Mikrobiyol Bul; 2014 Jan; 48(1):123-8. PubMed ID: 24506722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report.
    Swoboda S; Fritz S; Martignoni ME; Feldhues RA; Hoppe-Tichy T; Buchler MW; Geiss HK
    J Antimicrob Chemother; 2005 Oct; 56(4):787-9. PubMed ID: 16143710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
    Streit JM; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2004 Feb; 48(2):137-43. PubMed ID: 14972384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
    Dowzicky MJ; Chmelařová E
    Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
    Jones RN; Fritsche TR; Sader HS; Goldstein BP
    J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of dalbavancin against enterococci isolates from wild animals, pets, poultry and humans in Portugal.
    Poeta P; Radhouani H; Sargo R; Igrejas G
    J Basic Microbiol; 2008 Dec; 48(6):526-8. PubMed ID: 18798175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
    Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
    Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
    Anderegg TR; Sader HS; Fritsche TR; Ross JE; Jones RN
    Int J Antimicrob Agents; 2005 Jul; 26(1):13-21. PubMed ID: 15967640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
    Pfaller MA; Mendes RE; Duncan LR; Flamm RK; Sader HS
    J Antimicrob Chemother; 2018 Oct; 73(10):2748-2756. PubMed ID: 29982565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
    Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
    J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antimicrobial activity of linezolid tested against vancomycin-resistant enterococci isolated in Brazilian hospitals.
    Reis AO; Cordeiro JC; Machado AM; Sader HS
    Braz J Infect Dis; 2001 Oct; 5(5):243-51. PubMed ID: 11779450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS; Watters AA; Fritsche TR; Jones RN
    BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.